Jude Onyia Sells 20,362 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Jude Onyia sold 20,362 shares of the stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $130.13, for a total value of $2,649,707.06. Following the sale, the insider owned 18,289 shares in the company, valued at approximately $2,379,947.57. This trade represents a 52.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Neurocrine Biosciences Trading Up 0.7%

NASDAQ NBIX traded up $0.86 on Tuesday, hitting $128.74. 753,911 shares of the company's stock traded hands, compared to its average volume of 1,141,913. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $157.98. The firm has a market capitalization of $12.74 billion, a PE ratio of 43.64, a P/E/G ratio of 1.32 and a beta of 0.24. The firm's 50-day moving average price is $122.20 and its two-hundred day moving average price is $121.53.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The company had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The business's revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.20 earnings per share. On average, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on NBIX. JPMorgan Chase & Co. upped their price objective on Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 26th. Canaccord Genuity Group upped their price target on shares of Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Wedbush reiterated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Tuesday, May 6th. BMO Capital Markets lifted their price target on Neurocrine Biosciences from $96.00 to $115.00 and gave the company a "market perform" rating in a report on Tuesday, May 6th. Finally, HC Wainwright lowered their price objective on Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. Three analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $162.00.

Institutional Investors Weigh In On Neurocrine Biosciences

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of Neurocrine Biosciences by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company's stock valued at $1,381,331,000 after purchasing an additional 122,681 shares during the period. Dodge & Cox raised its holdings in Neurocrine Biosciences by 83.5% during the first quarter. Dodge & Cox now owns 5,534,624 shares of the company's stock worth $612,129,000 after purchasing an additional 2,518,199 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Neurocrine Biosciences by 44.0% in the 1st quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company's stock worth $232,037,000 after buying an additional 640,556 shares in the last quarter. AQR Capital Management LLC increased its position in Neurocrine Biosciences by 2.9% during the fourth quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company's stock worth $258,926,000 after buying an additional 53,610 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Neurocrine Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company's stock valued at $255,523,000 after purchasing an additional 15,830 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.